Multi-Institutional Study Data Presented at ASTRO 2023 Builds Upon Growing Evidence of GammaTile for Patients with Brain Tumors
GT Medical Technologies, Inc. announced interim findings of a multi-institutional study that demonstrates high local control for the treatment of recurrent brain metastases in patients. The findings were presented during the American Society for Radiation Oncology's (ASTRO) 65th Annual Meeting, ASTRO 2023, being held this week in San Diego, CA.
Source: itnonline.com
